Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICAM1-MMAE
- Development stage
- Preclinical
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
ICAM1-MMAE is an antibody-drug conjugate (ADC) designed to target intercellular adhesion molecule-1 (ICAM1), a protein identified as being upregulated in ovarian cancer and expressed on both malignant epithelial cells and cancer-associated fibroblasts (CAFs). By targeting both the tumor cells and the supportive stroma, the drug aims to overcome stromal barriers and microenvironment-driven resistance that often limit the efficacy of epithelial-restricted therapies. The ADC consists of an ICAM1-targeting antibody conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE). Preclinical studies have demonstrated that ICAM1-MMAE exhibits potent cytotoxicity against ovarian cancer cells and ICAM1-positive CAFs, leading to significant tumor regression and stromal remodeling, including the depletion of alpha-SMA-positive fibroblasts and reduced collagen deposition in the extracellular matrix.
- Other names
- ICAM1 antibody-drug conjugateICAM-1 antibody-drug conjugateICAM 1 antibody-drug conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on ICAM1-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICAM1-MMAE.